Mateo Mejia Saldarriaga, MD

Highlights

1
Blood advances · 2024
MMMateo Mejia Saldarriaga JFJoshua Fein RNRoger N Pearse GGGiorgio Ga. Inghirami+1 more →MBMark Bustoros
PMID: 38776397PMCID: PMC11321283DOIFirst author36 citations
2
Cancer journal (Sudbury, Mass.) · 2021
MMMateo Mejia Saldarriaga
PMID: 34549905DOIFirst author
3
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
MMMateo Mejia Saldarriaga
PMID: 41385751DOIFirst author

Completed grants (1)

MPI
Characterization of the genomic and transcriptional landscape and role of tumor immune environment in multiple myeloma with extramedullary disease
Conquer Cancer Foundation of the American Society of Clinical Oncology · 2022–2024
ASCO 221200-01

3 studies

PI
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
PHASE3 · Juno Therapeutics, Inc. · OPEN TO ACCRUAL (as of 2026)
Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06615479
PI
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
PHASE3 · GlaxoSmithKline · OPEN TO ACCRUAL (as of 2026)
Multiple Myeloma; Newly Diagnosed Multiple Myeloma
NCT06679101
PI
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM
PHASE1; PHASE2 · AbbVie Inc. · OPEN TO ACCRUAL (as of 2025)
Multiple Myeloma
NCT06892522

Completed & closed trials (4)

PI
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
PHASE2 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2025)
Multiple Myeloma
NCT06169215
PI
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
PHASE1; PHASE2 · Indapta Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2025)
NHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma
NCT06119685
PI
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
Amyloid; AL Amyloidosis; Refractory AL Amyloidosis
NCT04270175
PI
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
Multiple Myeloma; Refractory Multiple Myeloma; Relapse Multiple Myeloma
NCT04302324

Blood Test May Guide Use of Multiple Myeloma Immunotherapy
July 24, 2024
A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research.

Johnson & Johnson